阿戈美拉汀治疗精神分裂症伴发的抑郁：病例系列
Agomelatine for Depression in Schizophrenia: A Case-Series.
作者信息
Mutschler Jochen, Rüsch Nicolas, Schönfelder Herdis, Herwig Uwe, Brühl Annette B, Grosshans Martin, Rössler Wulf, Russmann Heike
机构信息
Drs. Mutschler, MD, Rüsch, MD, Schönfelder, MD, Herwig, MD, Brühl, MD, Rössler, MD, Russmann, MD, Department of General and Social Psychiatry, Psychiatric University Hospital Zürich, Militärstrasse 8, Zürich, Switzerland. Dr. Grosshans, MD, Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim J5, Germany.
出版信息
Psychopharmacol Bull. 2012 Feb 15;45(1):35-43.
OBJECTIVES
Agomelatine, a melatonin (MT1/MT2) receptor agonist and 5-HT2C receptor antagonist, is a new antidepressant and a potential therapeutic option for major depressive episodes and negative symptoms in persons with schizophrenia. We investigated such treatment outcomes with respect to antidepressant efficacy, safety, and tolerability.
METHODS
We report a consecutive case series of seven patients with schizophrenia and comorbid major depressive symptoms who received agomelatine for a period of at least six weeks in addition to stable doses of antipsychotic agents. General psychopathology, positive, negative and depressive symptoms were assessed with standardized interviews. Relevant blood parameters were assessed.
RESULTS
Depressive symptoms improved significantly. Positive symptoms remained stable, while negative symptoms and global psychopathology improved significantly. Agomelatine was well tolerated in most patients.
CONCLUSIONS
Our findings provide initial evidence that agomelatine is safe and efficacious in treating depressive symptoms in patients with schizophrenia. Furthermore, agomelatine seems to be effective for the treatment of negative symptoms. Randomized controlled trials are necessary to confirm these first observations.
目的
阿戈美拉汀是一种褪黑素（MT1/MT2）受体激动剂和5-羟色胺2C受体拮抗剂，是一种新型抗抑郁药，也是治疗精神分裂症患者重度抑郁发作和阴性症状的一种潜在治疗选择。我们研究了其在抗抑郁疗效、安全性和耐受性方面的治疗结果。
方法
我们报告了一个连续病例系列，7例患有精神分裂症且伴有重度抑郁症状的患者，除了稳定剂量的抗精神病药物外，还接受了至少六周的阿戈美拉汀治疗。通过标准化访谈评估一般精神病理学、阳性、阴性和抑郁症状。评估相关血液参数。
结果
抑郁症状显著改善。阳性症状保持稳定，而阴性症状和整体精神病理学显著改善。大多数患者对阿戈美拉汀耐受性良好。
结论
我们的研究结果提供了初步证据，表明阿戈美拉汀在治疗精神分裂症患者的抑郁症状方面是安全有效的。此外，阿戈美拉汀似乎对阴性症状的治疗有效。需要进行随机对照试验来证实这些初步观察结果。
Zotero 插件